The primary objective is to evaluate the safety of autologous cardiac-derived stem cells administered by intra-myocardial injection with the controlled release of bFGF in severe refractory heart failure patients with chronic ischemic cardiomyopathy. 12 month [clinicaltrials_resource:705df94ee2dfe8315d59d1112a032439]
single administration of 0.5 million cells/kg(patient body weight) of human cardiac stem cells and 200 microgram of bFGF at coronary artery bypass grafting (CABG)
clinicaltrials_vocabulary:primary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:primary-outcome]
The primary objective is to evaluate the safety of autologous cardiac-derived stem cells administered by intra-myocardial injection with the controlled release of bFGF in severe refractory heart failure patients with chronic ischemic cardiomyopathy. 12 month [clinicaltrials_resource:705df94ee2dfe8315d59d1112a032439]
single administration of 0.5 million cells/kg(patient body weight) of human cardiac stem cells and 200 microgram of bFGF at coronary artery bypass grafting (CABG)
Bio2RDF identifier
705df94ee2dfe8315d59d1112a032439
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:705df94ee2dfe8315d59d1112a032439
measure [clinicaltrials_vocabulary:measure]
The primary objective is to ev ...... ronic ischemic cardiomyopathy.
time frame [clinicaltrials_vocabulary:time-frame]
description
single administration of 0.5 m ...... artery bypass grafting (CABG)
identifier
clinicaltrials_resource:705df94ee2dfe8315d59d1112a032439
title
The primary objective is to ev ...... hemic cardiomyopathy. 12 month
@en
type
label
The primary objective is to ev ...... df94ee2dfe8315d59d1112a032439]
@en